-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TK-8001 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TK-8001 in Solid Tumor Drug Details: TK-8001 (T-1367) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TK-001 in Breast Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TK-001 in Breast Cancer Drug Details: TK-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Glioblastoma Multiforme (GBM)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Aglatimagene Besadenovec in Glioblastoma Multiforme (GBM) Drug Details:aglatimagene besadenovec is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Malignant Glioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Aglatimagene Besadenovec in Malignant GliomaDrug Details:aglatimagene besadenovec is under development for the treatment of non-small cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma Drug Details: aglatimagene besadenovec is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in High-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in High-Grade Glioma Drug Details: aglatimagene besadenovec is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Prostate Cancer Drug Details: aglatimagene besadenovec is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Non-Small Cell Lung Cancer Drug Details: aglatimagene besadenovec is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pexastimogene Devacirepvec in Metastatic Renal Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Pexastimogene Devacirepvec in Metastatic Renal Cell Carcinoma Drug Details:Pexastimogene devacirepvec (JX-594) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pexastimogene Devacirepvec in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pexastimogene Devacirepvec in Gastric Cancer Drug Details: Pexastimogene devacirepvec (JX-594) is under development for the...
-
Sector Analysis
New![]()
United Kingdom (UK) Town Centres Market Analysis by Sectors, Revenue Share, Consumer Attitudes, Key Players and Forecast to 2027
United Kingdom (UK) Town Centres Market Report Overview The UK town centres market size was GBP 102.8 billion in 2022. The market is expected to grow at a CAGR of more than 2% during 2022-2027. Retail sales in town centres are expected to grow at a slower rate than total retail sales in the UK over the forecast period, as e-commerce becomes more buoyant up to 2027. However, retailers can appeal to shoppers who want to shop offline by maintaining...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Octanorm in Primary Immune Deficiency (PID)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Octanorm in Primary Immune Deficiency (PID) Drug Details: Immunoglobulin G (Human) (Octonorm) contains mainly normal...
-
Sector Analysis
New![]()
United Kingdom (UK) Christmas Intentions – Analysing Buying Dynamics, Channel Usage, Spending and Retailer Selection
The GlobalData Retail Christmas Intentions 2023 report forms part of the Retail Occasions Series, and offers a comprehensive overview of the Christmas retail occasion ahead of the event, analysing consumers' intentions for spending.
-
Sector Analysis
New![]()
United Kingdom (UK) Home Personal Care Electricals Market Trends, Analysis, Consumer Dynamics and Spending Habits
The UK: Home Category Data, The Consumer - Personal care electircals 2023 report offers a comprehensive insight into consumer attitudes in the UK personal care electricals market. The report focuses on six key subcategories: overall personal care electricals, shavers, hairdryers, electric toothbrushes, hair styling, and beauty tools. Consumer data is based on our 2023 UK personal care electricals survey, using a panel of 2,000 nationally representative consumers.
-
Sector Analysis
New![]()
United Kingdom (UK) Off to University – Analysing Buying Dynamics, Channel Usage, Spending and Retailer Selection
The GlobalData Retail Off to University 2023 report forms part of the Retail Occasions series, and offers a comprehensive overview of the retail occasion of students starting and returning back to university, analysing the market, the major players, the main trends and consumer attitudes.
-
Consumer Insights
New![]()
United Kingdom (UK) Apparel Consumer Insights – Who Shops, What do they Shop, How do they Shop and Why do they Shop
The UK Apparel Consumer Insights Report provides consumer data and analysis from GlobalData's How Britain Shops Survey conducted in 2023. The report also includes some comparisons to consumer data from 2022. Over the 12 months to June 2023, 88.6% of UK consumers purchased apparel, driven by those aged 25-44 at 91.2%, with this demographic tending to have the greatest interest in fashion, and higher discretionary incomes than the younger age groups. With the UK amid a cost-of-living crisis, UK apparel...
-
Sector Analysis
New![]()
United Kingdom (UK) Retail Parks Market Size, Trends, Categories, Consumer Attitudes and Key Players to 2027
United Kingdom (UK) Retail Parks Market Report Overview The UK retail park market size was GBP 50.62 billion in 2022. The market is expected to grow at a CAGR of more than 2% during 2022-2027. The retail market will grow significantly during the forecast period driven by the online channel. Hence, to compete with online shopping, retail parks must improve the range of sectors available, making it a convenient location for consumers to do all their shopping. UK Retail Park...
-
Product Insights
![]()
TK Grp – Mirsarai Industrial Park – Chittagong
Equip yourself with the essential tools needed to make informed and profitable decisions with our TK Grp - Mirsarai Industrial Park - Chittagong report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
![]()
TK Kamchatskiy – Petropavlovsk-Kamchatsky Greenhouse Complex – Kamtsjatka
Equip yourself with the essential tools needed to make informed and profitable decisions with our TK Kamchatskiy - Petropavlovsk-Kamchatsky Greenhouse Complex - Kamtsjatka report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
![]()
BWSSB – TK Halli Water Treatment Plant – Karnataka
Equip yourself with the essential tools needed to make informed and profitable decisions with our BWSSB - TK Halli Water Treatment Plant - Karnataka report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.